Non-invasive methods permitting accurate detection of innate immune dysfunction are critical to enhance the understanding, diagnosis, and treatment of inflammatory disorders. Identifying specific biomarkers of innate immune cells and their functional phenotypes, paired with subsequent PET tracer development, is thus an area of great interest with important implications for a broad range of diseases. However, existing targets lack cell specificity and/or fail to provide functionally relevant information regarding immune cell status. To overcome these limitations, a PET tracer was developed targeting TREM1 a highly specific biomarker of pro-inflammatory myeloid-driven immune responses.

Non-invasive methods permitting accurate detection of innate immune dysfunction are critical to enhance the understanding, diagnosis, and treatment of inflammatory disorders. Identifying specific biomarkers of innate immune cells and their functional phenotypes, paired with subsequent PET tracer development, is thus an area of great interest with important implications for a broad range of diseases. However, existing targets lack cell specificity and/or fail to provide functionally relevant information regarding immune cell status. To overcome these limitations, a PET tracer was developed targeting TREM1 a highly specific biomarker of pro-inflammatory myeloid-driven immune responses.

Provided herein are protein contrast agents and targeted protein contrast agents, formulations thereof, and methods of use, including but not limited to, as a magnetic resonance imaging contrast agent.

Provided herein are protein contrast agents and targeted protein contrast agents, formulations thereof, and methods of use, including but not limited to, as a magnetic resonance imaging contrast agent.

Provided herein are protein contrast agents and targeted protein contrast agents, formulations thereof, and methods of use, including but not limited to, as a magnetic resonance imaging contrast agent.

Provided herein are protein contrast agents and targeted protein contrast agents, formulations thereof, and methods of use, including but not limited to, as a magnetic resonance imaging contrast agent.

The disclosure provides compositions comprising intercellular adhesion molecule 1 (ICAM1) antibody and methods for using the same for therapeutic applications, for example, treating pancreatic cancer and predicting drug response.

An improved method for diagnosing and characterizing peripheral nerve lesions to permit early identification and characterization of peripheral nerve injuries that will require surgical intervention.

An improved method for diagnosing and characterizing peripheral nerve lesions to permit early identification and characterization of peripheral nerve injuries that will require surgical intervention.

The present disclosure relates to compositions and methods of killing cells. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein, such as a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm.sup.−2. The cell is also contacted with one or more therapeutic agents (such as an anti-cancer agent), for example about 0 to 8 hours after irradiating the cell, thereby killing the cell. Also provided are methods of imaging cell killing in real time, using fluorescence lifetime imaging. Also provided are wearable devices that include an article of clothing, jewelry, or covering; and an NIR LED incorporated into the article, which can be used with the disclosed methods.